Ionis pharmaceuticals, inc. (IONS)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10Jun'10Mar'10
Operating activities:
Net income (loss)

-58,480

203,958

18,431

-10,011

90,884

302,732

-20,366

-56,569

-10,812

-9,167

-7,494

-3,086

8,964

52,021

7,351

-56,855

-62,917

-71,433

-35,776

35,648

-16,717

31,053

-26,676

-12,081

-31,280

-24,276

-24,570

-10,126

-1,672

-

-

-

-

-

-

-

-

-

-

-

-

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities
Depreciation

3,233

3,195

3,092

3,180

3,073

3,056

2,792

2,495

2,363

570

2,148

2,010

1,980

1,889

1,877

1,874

1,841

1,794

1,784

1,835

1,571

1,589

1,650

1,580

1,561

1,596

1,620

1,668

1,707

-

-

-

-

-

-

-

-

-

-

-

-

Amount of amortization expense attributable to right-of-use asset from operating lease.

393

109

398

559

476

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of patents

486

773

191

478

470

466

461

452

443

425

414

409

393

381

396

398

377

369

364

336

312

301

298

280

263

293

307

299

285

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of licenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

468

468

468

469

470

471

470

471

476

480

482

569

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of premium (discount) on investments, net

-1,062

421

1,901

2,730

2,433

1,804

1,054

-653

-1,192

-1,525

-1,669

-1,950

-1,608

-1,499

-1,521

-1,754

-2,039

-2,317

-2,118

-1,628

-1,749

-1,821

-1,802

-2,471

-1,376

-1,830

-1,360

-1,274

-1,108

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt issuance costs

595

494

491

483

474

467

490

412

441

414

405

401

396

315

309

303

298

292

286

280

275

183

140

137

135

107

106

102

100

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of convertible senior notes discount

8,834

10,591

9,086

8,935

8,726

8,582

8,417

8,281

8,083

7,957

7,800

7,657

7,506

6,152

6,029

5,914

5,795

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of long-term financing liability for leased facility

-

-

-

-

-

-

-

-

-

0

307

1,677

1,675

1,675

1,673

1,673

1,672

1,671

1,667

1,665

1,662

1,660

1,656

1,654

1,652

1,648

1,643

1,639

1,637

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of 2 3/4 percent convertible senior notes discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,606

1,566

1,543

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

40,790

35,010

24,127

41,932

45,505

34,102

34,883

33,876

28,451

22,333

21,472

21,258

20,912

15,158

17,586

19,261

20,103

17,407

14,997

13,605

13,305

8,489

8,117

7,708

7,069

3,100

2,813

2,636

2,869

-

-

-

-

-

-

-

-

-

-

-

-

Gain on investment in Regulus Therapeutics, Inc.

-

-

-

-

-

-

-

-

-

0

0

0

374

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill and an other than temporary decline in value that has been recognized against investments accounted for under the cost method of accounting.

-87

-

-

-

14

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on investments, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,116

3

-260

397

305

175

840

1,058

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash losses related to patents, licensing and property, plant and equipment

-

-

-

-

-

-

67

240

175

-

-532

36

93

-

670

68

396

-

78

73

93

2,058

-428

-217

-108

6,735

-166

-169

-94

-

-

-

-

-

-

-

-

-

-

-

-

Provision for deferred income taxes

-3,437

-

-10,333

887

13,549

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Tax benefit from other unrealized gains on securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-798

-12,835

1,395

881

-2,276

-

-

64

-64

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Contracts receivable

-34,429

13,958

17,461

21,163

-4,908

628

-2,030

-20,096

-26,097

20,031

-7,691

-18,742

-38,686

99,499

7,798

-15,734

5,124

9,530

-1,438

-23,670

23,031

-22,410

-15,628

32,118

-1,279

-1,543

10,621

852

650

-

-

-

-

-

-

-

-

-

-

-

-

Inventories

2,181

-1,195

870

3,261

2,475

204

-689

7

-922

1,531

1,947

-297

-688

-1,830

1,651

1,148

-379

316

-199

-57

549

-795

-691

239

-496

648

-924

2,500

-312

-

-

-

-

-

-

-

-

-

-

-

-

Other current and long-term assets

-9,532

21,282

17,005

7,698

-1,326

2,775

21,396

16,599

-11,422

23,501

-4,505

25,294

14,077

-1,629

-2,550

-171

2,747

-9,063

-1,172

12,178

2,451

511

544

-201

896

-444

1,043

-1,109

1,601

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

411

2,421

-2,660

1,087

-17,191

12,951

633

-1,095

-13,144

3,491

8,323

-10,502

472

4,523

-2,764

-1,019

-11,417

8,349

9,059

-5,502

-2,695

3,410

-577

4,637

-2,646

2,359

-460

3,736

-5,569

-

-

-

-

-

-

-

-

-

-

-

-

Accrued compensation

-20,920

12,953

4,355

3,785

-13,004

5,009

9,170

2,923

-12,985

9,964

4,889

2,031

-15,919

13,178

3,567

1,104

-9,728

6,557

1,593

2,504

-6,891

5,138

734

2,102

-7,840

5,515

-378

3,213

-4,060

-

-

-

-

-

-

-

-

-

-

-

-

Other current liabilities

-2,565

-

-

-

13,756

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

105

62

27

57

44

25

44

75

58

40

-

-

-

-

-

-

-

-

-

-

-

-

Accrued liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6

-6,704

1,312

5,081

-678

2,643

6,248

578

-2,490

2,355

-

-

-

-

-

-

-

-

-

-

-

-

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and deferred liabilities due within one year or operating cycle.

-

-

-

-

-

-

-6,174

-6,523

-1,695

-

-4,102

5,124

-6,273

-

5,509

-7,146

-1,886

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred contract revenue

-19,679

-22,254

-23,386

-33,290

-40,353

47,086

-36,646

511,602

-27,788

-889

-24,517

-20,347

75,935

-42,048

-12,539

-15,870

-14,849

-15,608

50,823

-5,256

-7,841

17,169

-9,606

-13,236

-5,742

-16,058

91,390

21,533

-8,521

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) operating activities

-7,584

277,932

-12,806

-27,111

107,705

115,490

-26,004

500,237

13,165

20,401

28,720

2,363

122,665

-26,839

24,286

-33,784

-75,768

-37,474

36,218

65,207

-42,826

70,684

1,944

-34,015

-32,328

-14,492

65,821

22,740

-10,576

36,035

-24,871

-2,577

-6,711

-22,741

-23,169

-26,177

-39,842

-25,503

-21,429

5,030

-21,691

Investing activities:
Purchases of short-term investments

544,375

329,000

568,452

556,493

492,781

638,400

507,433

557,745

91,157

288,155

241,739

81,731

266,185

66,426

152,672

40,448

41,366

95,391

157,506

200,357

40,213

141,303

71,384

110,011

69,185

121,692

159,612

79,698

64,552

45,296

55,928

54,812

61,841

86,729

75,656

98,559

110,164

100,506

103,468

200,565

125,598

Proceeds from sale of short-term investments

459,352

486,134

587,634

451,098

426,868

314,307

204,469

190,324

173,724

243,509

111,385

103,252

99,223

86,601

97,813

98,353

81,805

126,475

105,587

109,062

78,460

71,831

47,119

80,489

95,288

37,632

38,204

47,850

49,076

53,262

46,716

80,900

61,781

117,046

73,695

127,849

170,328

94,057

181,203

143,652

158,621

Purchases of property, plant and equipment

9,080

7,762

15,900

4,014

3,229

1,387

3,244

6,634

2,343

8,262

17,049

6,216

3,237

2,794

1,050

2,635

628

2,411

1,341

3,062

878

3,549

869

1,697

1,403

439

522

369

222

446

169

751

113

1,269

2,952

3,406

2,576

497

846

885

11,009

Proceeds from land sold to BioMed

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

10,147

Reduction of cash due to deconsolidation of Regulus Therapeutics Inc. upon adoption of a new accounting standard

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

16,228

The cash outflow for acquisition of licenses and other assets not otherwise defined in the taxonomy.

904

1,181

1,886

1,278

1,032

727

1,463

1,116

738

-1,196

2,696

610

983

1,047

1,179

1,813

382

722

1,585

1,030

719

1,143

652

1,458

333

1,089

1,550

469

702

912

1,187

1,243

349

1,123

789

1,244

511

889

975

1,939

516

Proceeds from the sale of Regulus Therapeutics, Inc.

-

-

-

-

-

-

-

-

-

0

0

0

2,507

4,467

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-95,007

138,191

1,396

-110,687

-70,174

-326,207

-307,671

-375,171

79,486

-54,212

-150,099

14,695

-168,675

20,801

-57,088

53,457

39,429

27,964

-29,279

-95,387

36,650

-50,788

-24,487

-32,394

24,821

-85,270

-123,308

-31,842

-15,306

5,035

-10,608

24,094

-522

32,370

-5,702

24,640

56,718

-7,242

75,914

-59,936

14,958

Financing activities:
Proceeds from issuance of equity, net

7,652

7,520

10,133

34,947

67,057

9,646

8,076

4,503

5,675

5,259

7,745

3,603

6,324

6,163

3,134

1,384

2,736

4,613

2,240

3,919

14,116

-

4,293

1,413

12,003

6,060

20,019

25,056

11,823

1,681

6,172

979

638

2,013

678

193

683

2,320

754

251

1,031

Payments of tax withholdings related to vesting of employee stock awards and exercise of employee stock options

11,603

401

10,807

437

7,597

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of strategic investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

359

-408

0

199

459

Proceeds from the sale of strategic investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

427

1,299

283

454

318

172

844

1,094

-

-

-

-

-

-

-

-

-

-

-

-

Repurchases and retirements of common stock

90,600

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Principal payments on debt and capital lease obligations

-

-

-

-

-

-

-

-

-

22

299

1,638

1,640

1,638

1,711

1,860

1,857

1,795

2,073

2,600

2,590

2,584

2,611

2,701

2,691

2,733

2,733

2,800

2,773

2,840

2,746

2,342

2,491

1,428

1,566

1,459

1,411

1,256

1,155

980

963

Proceeds from the issuance of common stock

-

-

-

-

-

-

-

-

-

-

-

-

71,640

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Offering costs paid

-

-

-

-

-

-

-

-

451

980

26

253

778

-62

880

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-94,501

19,225

-13,174

34,510

59,460

9,646

8,076

452,919

5,224

4,257

147,572

1,712

75,546

6,448

4,543

-476

879

11,714

167

1,319

11,526

49,882

1,682

-1,288

9,312

3,327

17,355

197,992

9,050

-1,151

34,397

7,737

-1,853

585

-888

359

-728

2,675

-401

2,354

68

Net increase in cash and cash equivalents

-197,092

435,348

-24,584

-103,288

96,991

-201,071

-325,599

577,985

97,875

-29,554

26,193

18,770

29,536

410

-28,259

19,197

-35,460

2,204

7,106

-28,861

5,350

69,778

-20,861

-67,697

1,805

-96,435

-40,132

188,890

-16,832

39,919

-1,082

29,254

-9,086

10,214

-29,759

-1,178

16,148

-30,070

54,084

-52,552

-6,665

Supplemental disclosures of cash flow information:
Interest paid

601

4,396

698

4,109

667

4,158

681

4,109

644

4,015

413

3,501

106

3,018

881

3,383

31

2,567

856

3,340

37

3,376

57

2,837

83

2,921

102

2,864

113

186

3,309

64

2,211

157

2,249

123

2,275

195

2,281

132

2,281

Income taxes paid

3

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

2

-

-

-

-

0

0

0

2

-430

0

0

7,700

Supplemental disclosures of non-cash investing and financing activities:
Right-of-use assets obtained in exchange for lease liabilities

0

0

258

363

13,557

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Future cash outflow to pay for purchases of fixed assets and patents that have been incurred.

4,903

-125

178

1,209

1,864

2,132

-349

554

2,091

-1,492

1,770

57

1,648

918

859

-862

2,524

715

-719

-32

1,198

-1,053

2,751

-1,053

1,506

-131

-220

340

715

-192

160

-165

844

-476

298

-142

1,222

-5

96

-5

836

Future cash outflow to pay for deferred offering costs attributable to an offering of securities that have been incurred.

-

-

-

-

-

-

-

-

-

-

165

154

319

240

-328

379

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-